Dimerix (ASX:DXB) announced that its first patient completed a two-year open-label extension study, marking four continuous ...

Dimerix’s DMX-200 program reaches a milestone as its first patient completes two years in the extension study, with 93% of ...

The first patient has completed two years in the DMX-200 OLE study after finishing the two-year ACTION3 Phase 3 trial, ...

I took a flight on an Australian airline with a very unexpected business class product.

In an emergency at sea, there is no second chance. If a lifeboat engine fails to start, an emergency generator cannot take load, or a diesel driven fire pump loses power, the consequences can be ...

Cash Flow Statement for Dien May Xanh Investment JSC, company's cash and cash equivalents, broken down to operating, investing and financing activities.

The patent titled N-cyanopyrrolidines with activity as USP30 inhibitors has been issued to Dimerix (ASX:DXB) under patent number 438406 by the Mexican Institute of Industrial Property (IMPI). It ...

Dimerix secured a composition of matter patent in Mexico for its acute kidney injury candidate, DMX-652. The patent expands global intellectual property protection as the company prepares the ...

DMX Asset Management Reports Voting Power Increase As per the filing, the prior notice to Kip McGrath Education Centres Limited was submitted on 21 October 2025. The current notice, dated 28 August ...

Kip McGrath Education Centres Limited (ASX:KME) has received a notice of change of interests of substantial shareholder from DMX Asset Management Limited, disclosing that its voting power in the ...